Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Beta Finch - Pharma & Biotech - EN cover art

Beta Finch - Pharma & Biotech - EN

Beta Finch - Pharma & Biotech - EN

Written by: Beta Finch
Listen for free

About this listen
Leading pharmaceutical and biotechnology companies. AI-powered earnings call analysis for Pharma & Biotech (PHARMA). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Zoetis Q3 2026 Earnings Analysis
    Nov 6 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Zoetis, ticker ZTS, and their third quarter 2026 results, which came out this morning.

    **JORDAN:** Lots to unpack here — derm wars, screwworms, and a guy named Jay on his very first earnings call. Should be fun.

    **ALEX:** It will be. But first, our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Good, now let's get into it.

    **ALEX:** So Zoetis is the big animal health company — pet meds, livestock vaccines, diagnostics. Q3 revenue came in at $2.4 billion, down about 1% both reported and organically. That was basically in line with what management expected going in.

    **JORDAN:** Adjusted EPS, though, actually ticked up 1% to $1.75, mostly thanks to a lower share count from buybacks, not operational strength. So it's a bit of financial engineering helping the bottom line while the top line stays soft.

    **ALEX:** Right, and the U.S. segment was the weak spot — down 6% to $1.2 billion. International was actually the bright spot, up 4% to $1.1 billion, with livestock, parasiticides, and OA pain more than offsetting dermatology headwinds overseas.

    **JORDAN:** And dermatology is really the story of this quarter. Key derm sales fell 16% globally to $396 million. In the U.S., Apoquel lost share to new competitors, though the chewable version is now half of Apoquel's volume, which shows some stickiness there.

    **ALEX:** And Cytopoint actually held up better than expected — management said the new injectable competitor's impact was minimal so far, partly because that competitor has had supply issues.

    **JORDAN:** Here's a stat that stuck with me: U.S. canine visits were down about 5%, pruritic — meaning itchy-skin — visits down 3%. So it's not just competition, it's genuinely softer clinic traffic. Pet owners are being more careful with spending.

    **ALEX:** Which ties into something CEO Kristin Peck mentioned — vet service costs are up 50% since 2022, way outpacing general inflation. That's squeezing pet owners and changing behavior.

    **JORDAN:** Right, and even the pet population mix is shifting — more cats, fewer dogs, because of housing costs affecting adoption. Dogs are more "medicalized," as they put it, so that mix shift actually weighs on demand for vet services overall.

    **ALEX:** Now, the good news: management said their defensive playbook is working. They used targeted promotional spending — what they call "gross-to-net" investments rather than cutting list prices — to slow the bleeding. Derm share loss improved from 7 points lost in Q2 to just 4 points in Q3.

    **JORDAN:** And in parasiticides, Simparica Trio held its U.S. share at 22.5%, still roughly double the next competitor, and they remain the leader in new puppy starts, which is a nice leading indicator for future sales.

    **ALEX:** On the innovation front, there's real stuff coming. Long-acting Cytopoint is expected to get FDA approval in Q4, launching in the first half of 2027. Simparica Duo approval is now expected by year-end, ahead of schedule.

    **JORDAN:** And don't skip over livestock — that segment grew 7% to $797 million, with strength in cattle, swine, poultry vaccines, and even fish vaccines in Norway. Global protein demand is just a steady tailwind there, offsetting the companion animal softness nicely. Diversification is really earning its keep this quarter.

    **ALEX:** Diagnostics also grew double digits — 13% to $122 million — boosted by the VitalRADS and VPG acquisitions plus organic adoption of their point-of-care platforms.

    **JORDAN:** Now let's talk guidance, because this is where it gets interesting. Zoetis narro

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
  • Pfizer Q3 2026 Earnings Analysis
    Nov 4 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Pfizer's third quarter 2026 results, reported on November 3rd. And Alex, there's actually a leadership headline buried in here too.

    ALEX: There is, we'll get to that. But first, the standard stuff — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good, now let's get into it. Pfizer's got a lot going on this quarter.

    ALEX: It really does. Let's start with the numbers. Q3 revenue came in at $17.6 billion — I know the transcript says "$617 billion" but that's clearly a transcription error, context makes clear it's in the $17-18 billion range for the quarter. The real headline though: non-COVID revenue grew 7% operationally, and here's the kicker — their newer, launched and acquired products grew 32% operationally. That's a huge number.

    JORDAN: And that 32% growth is really the story of this earnings call. We're talking about products like Padcev, which came from the Seagen acquisition, Nurtec for migraine from Biohaven, and Lorbrena in oncology. These aren't the legacy blockbusters — these are the bets Pfizer made to replace revenue they're going to lose to patent expirations.

    ALEX: Right, and speaking of those patent cliffs — Eliquis, Ibrance, Xtandi are all facing loss of exclusivity pressure in the next couple years. So this transition story is really about: can the new stuff grow fast enough to offset what's rolling off?

    JORDAN: And based on this quarter, the answer looks like yes, at least for now. Adjusted EPS came in at $0.87, beating expectations, even with a $0.10 charge tied to the Innovent transaction. And because of that strength, management raised full-year revenue guidance to $62 billion to $64 billion, and bumped adjusted EPS guidance to $2.95 to $3.05.

    ALEX: Raising guidance is always a good sign — it tells you management has confidence in the back half of the year. Let's talk about the leadership change you mentioned.

    JORDAN: Yeah, Cecile Guegan stepped in as the new CFO this quarter, bringing over 25 years of finance experience. She emphasized "financial discipline" and "rigorous capital allocation" — basically signaling continuity with the strategy Pfizer's been running, not a dramatic pivot.

    ALEX: That continuity matters because Pfizer's been in the middle of this massive productivity push — they're targeting $7.2 billion in net cost savings by the end of this year, and they've already announced a second phase targeting another $2.5 billion in savings from 2027 through 2029.

    JORDAN: Which is important because, as one analyst pointed out on the call, total R&D and SG&A spending hasn't actually dropped much since 2022 — it's roughly flat around $24-25 billion. So the savings are happening, but they're getting plowed right back into R&D, especially oncology and obesity programs. Management's argument is these are "good" reinvestments, not wasted spend.

    ALEX: Let's talk pipeline, because this call had a lot of meaty clinical updates. The obesity program is clearly a big strategic bet — they're running 10 active or planned Phase 3 trials in 2026 for their GLP-1 franchise, including berobenatide, a monthly injectable they're hoping to get approved starting around 2028.

    JORDAN: And in oncology, there were some really interesting data points. Elrexfio, their multiple myeloma drug, had a second positive Phase 3 readout. CEO Albert Bourla actually got pretty feisty about this during Q&A — he pointed out that Wall Street analysts are modeling around $600 million in peak sales for Elrexfio, while a competing drug with a similar profile is projected at $5 billion. He fla

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
  • Vertex Pharmaceuticals Q3 2026 Earnings Analysis
    Nov 3 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' third quarter 2026 results, and this one is packed with news. I'm Alex.

    **JORDAN:** And I'm Jordan. Vertex is quietly transforming from a cystic fibrosis company into something much bigger, and this quarter really drives that home.

    **ALEX:** Before we jump in, quick reminder: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Alright, let's get into the numbers.

    **ALEX:** Vertex posted 12% year-over-year revenue growth in Q3, with 10% growth domestically and 16% internationally. That's a nicely balanced global story. And they raised full-year guidance to a range of $13.15 billion to $13.25 billion.

    **JORDAN:** What stood out to me is *where* that growth is coming from. Yes, cystic fibrosis is still the backbone—$3.3 billion in the quarter, up 8%—but the real excitement is in the newer stuff. CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, hit $99 million, up 30% sequentially. And JOURNAVX, the non-opioid pain medicine, brought in $58 million with over 750,000 prescriptions in the quarter alone.

    **ALEX:** JOURNAVX is actually now the number one prescribed branded oral analgesic in the U.S. That's a big milestone for a drug that's trying to change decades of prescribing habits around pain management.

    **JORDAN:** Right, and management is playing a long game there. They're keeping a patient support program running through 2027 to make sure patients get access even before insurance fully catches up. That's actually suppressing reported revenue right now because of gross-to-net dynamics, but it sets up for a cleaner growth trajectory once that program sunsets.

    **ALEX:** Now here's the headline strategic move: Vertex closed its $9 billion acquisition of Crinetics Pharmaceuticals, which gives them Palsonify, an oral treatment for acromegaly. This is officially their fourth commercial pillar, and management says they're on the verge of a fifth—renal medicine—pending a PDUFA decision on povitacept for IgA nephropathy on November 30th. That's just weeks away.

    **JORDAN:** That's the part I find most interesting. Vertex is essentially building a five-pillar company in real time—CF, hematology, pain, rare endocrine, and soon renal. Palsonify only contributed for one month post-close but still brought in $10 million in September alone, and full Q3 contribution was about $24 million. Early metrics look healthy too—roughly 500 endocrinologists are already writing prescriptions, with leading market share among new and switching patients.

    **ALEX:** On the earnings side, non-GAAP net income came in at $1.21 billion, or $4.76 per share. Gross margin was strong at 85.6% on a non-GAAP basis. But operating expenses are climbing—they revised full-year opex guidance up to approximately $6 billion, largely to absorb Crinetics integration costs and continued commercial scale-up for these launches.

    **JORDAN:** That's the trade-off here. Vertex is spending aggressively to support five simultaneous launches and a major acquisition integration. SG&A was up 51% year-over-year in the quarter, with most of that going toward commercial infrastructure for povitacept, JOURNAVX, and Palsonify.

    **ALEX:** Let's talk about the Q&A, because there were some meaty exchanges. Analysts pushed hard on povitacept—there was even a citizen's petition raising questions about IgG monitoring requirements. CEO Reshma Kewalramani addressed it head-on, noting that serious infection rates were balanced between drug and placebo arms in their trial, and that everything happening with the FDA review is proceeding a

    This episode includes AI-generated content.
    Show More Show Less
    6 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet